Licensing
Dr. Gene Emmer, President of Med Services
Dr. Emmer explained further about the opportunity that this portfolio presents to pharmaceutical companies “The media has sensationalized the recent findings of the Women’s Health Initiative (WHI) and there has been a strong over-reaction to the study’s findings. This has caused many competitors to abandon this market. However, most physicians agree that HRT is the only effective therapy for climacteric symptoms of menopause, commonly known as hot-flashes, or hot-flush, which can be extremely disabling for a large population of women. The market for HRT products is very large and growing due to ageing of the population and it is hungry for new launches. This portfolio offers many interesting advantages for the market and for the pharmaceutical companies that will represent them”
Dr Emmer encourages pharmaceutical companies to learn more about the opportunity to in-license this portfolio of products. “This is a unique opportunity to obtain marketing rights to an exciting portfolio of products, which are effective for a large and growing market. The media attention to WHI has served to decrease the competitive noise in this market and make this an exciting time for companies coming with a new message.”
Pharmaceutical companies interested in obtaining more information may contact Dr Emmer at Med Services Europe in
About Med Services
Med Services Europe GmbH is located in